Raphael Pharmaceutical Inc. 10-K Cybersecurity GRC - 2024-03-28

Page last updated on April 11, 2024

Raphael Pharmaceutical Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-28 16:16:01 EDT.

Filings

10-K filed on 2024-03-28

Raphael Pharmaceutical Inc. filed an 10-K at 2024-03-28 16:16:01 EDT
Accession Number: 0001213900-24-027234

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cyber Security. The Company maintains cybersecurity procedures to mitigate risk and to ensure compliance with security, availability, and confidentiality. The cybersecurity process is integrated into the Company s overall risk management system and is solely internally managed. The Company s Chief Financial Officer is responsible for identifying risks that threaten achievement of the control activities made by the Company. The risk assessment occurs as business needs change and covers identification of risks that could act against the company s objectives. The level of each identified risk is determined by the Company Chief Financial Officer, considering the impact of the risk itself and the likelihood of the risk materializing. As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. Cyber Security Risk Management and Strategy As part of the Company s cybersecurity risk management program, we are focused on the following key areas: Governance: As discussed in more detail under the heading Governance below, as part of its general oversight duties, the Board oversees the Company s risk management, including the cyber security risks. Technical Safeguards: The Company deploys commensurate technical safeguards, including firewalls, encryption, network segmentation, real-time monitoring, intrusion prevention systems, anti-malware, and access controls. Continuous Review: The Company regularly reviews its cybersecurity standards, and procedures and evaluates the effectiveness of implemented security controls. The Company adjusts its cybersecurity standards and programs as necessary. Governance The Board oversees our risk management process and receive regular updates and information on cybersecurity risks, if any, which address recent developments, evolving standards, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The Board also receive timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed.


Company Information

NameRaphael Pharmaceutical Inc.
CIK0001415397
SIC DescriptionMedicinal Chemicals & Botanical Products
TickerRAPH - OTC
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30